● Recruiting

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

Condition: Chronic Hepatitis B Infection · Sponsor: Aligos Therapeutics

PhasePhase 1

Planned participants30

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersYes

About this study

This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.

This description comes directly from the study's public registry record.

Talk to the study team

Aligos Therapeutics Therapeutics · (800) 466-6059 · info@aligos.com

Always discuss trial participation with your own doctor first.

Locations (2)

Orlando Clinical Research Center	Orlando, Florida, United States	Recruiting
Genesis Clinical Trials	Tampa, Florida, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07342881